{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-044372","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.115817+00:00","generated_at":"2026-05-22T16:04:43.734115+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties","bullets":["Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.","Annual $2M service fee plus $8M milestone if Takeda gets marketing approval; $5M of milestone creditable.","Profit share replaced with tiered royalty on net sales in mid-to-high teens, effective April 1, 2024.","Takeda may develop a different vaccine strain but must procure it from Novavax.","Parties also entered release agreement settling all claims related to original 2021 pact."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-044372","json":"https://secwatch.observer/filing/0001104659-25-044372.json","markdown":"https://secwatch.observer/filing/0001104659-25-044372.md","text":"https://secwatch.observer/filing/0001104659-25-044372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/0001104659-25-044372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/tm2513960d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:04:43.734115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}